5TX Stock Overview
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sensus Healthcare, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.70 |
| 52 Week High | US$5.85 |
| 52 Week Low | US$1.74 |
| Beta | 0.93 |
| 1 Month Change | 87.50% |
| 3 Month Change | 28.09% |
| 1 Year Change | 112.85% |
| 3 Year Change | 108.03% |
| 5 Year Change | n/a |
| Change since IPO | 150.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5TX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 21.8% | 0.8% | -0.3% |
| 1Y | 112.8% | -3.3% | 4.5% |
Return vs Industry: 5TX exceeded the German Medical Equipment industry which returned -3.3% over the past year.
Return vs Market: 5TX exceeded the German Market which returned 4.5% over the past year.
Price Volatility
| 5TX volatility | |
|---|---|
| 5TX Average Weekly Movement | 15.9% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5TX's share price has been volatile over the past 3 months.
Volatility Over Time: 5TX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 35 | Joe Sardano | sensushealthcare.com |
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Sensus Healthcare, Inc. Fundamentals Summary
| 5TX fundamental statistics | |
|---|---|
| Market cap | €94.54m |
| Earnings (TTM) | €4.29m |
| Revenue (TTM) | €29.16m |
20.9x
P/E Ratio3.1x
P/S RatioIs 5TX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5TX income statement (TTM) | |
|---|---|
| Revenue | US$31.65m |
| Cost of Revenue | US$12.55m |
| Gross Profit | US$19.10m |
| Other Expenses | US$14.45m |
| Earnings | US$4.65m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 60.34% |
| Net Profit Margin | 14.70% |
| Debt/Equity Ratio | 0% |
How did 5TX perform over the long term?
See historical performance and comparison